NCT05444556View on ClinicalTrials.gov

A Study of Imlunestrant (LY3484356) in Female Healthy Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

113

Participants

Timeline

Start Date

July 7, 2022

Primary Completion Date

November 2, 2022

Study Completion Date

November 2, 2022

Conditions
Healthy
Interventions
DRUG

Imlunestrant

Administered orally.

DRUG

Repaglinide

Administered orally.

DRUG

Omeprazole

Administered orally.

DRUG

Dextromethorphan

Administered orally.

DRUG

Quinidine

Administered orally.

DRUG

Rosuvastatin

Administered orally.

DRUG

Digoxin

Administered orally.

Trial Locations (3)

78209

ICON Early Phase Services, San Antonio

90630

Altasciences Clinical Los Angeles, Inc, Cypress

33143-4875

Qps-Mra, Llc, South Miami

All Listed Sponsors
lead

Eli Lilly and Company

INDUSTRY